BR0010380A - Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos - Google Patents

Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos

Info

Publication number
BR0010380A
BR0010380A BR0010380-2A BR0010380A BR0010380A BR 0010380 A BR0010380 A BR 0010380A BR 0010380 A BR0010380 A BR 0010380A BR 0010380 A BR0010380 A BR 0010380A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
combination
kit
pharmaceutical composition
Prior art date
Application number
BR0010380-2A
Other languages
English (en)
Inventor
Pancras C Wong
Shaker A Mousa
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR0010380A publication Critical patent/BR0010380A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODO COMPOSIçãO FARMACêUTICA, KIT E USO DE UMA COMBINAçãO PARA PREVENçãO E TRATAMENTO DE DIVERSAS DISFUNçõES TROMBOEMBóLICAS E MéTODOS DE TRATAMENTO DE TROMBOSE EM MAMìFEROS". A presente invenção refere-se a uma terapia de combinação que compreende a administração de uma heparina de baixo peso molecular, tal como tinzaparina, e um antagonista de plaquetas GPIIb/IIIa, tal como roxifiban, para o tratamento, prevenção e redução do risco de disfunções tromboembólicas.
BR0010380-2A 1999-03-11 2000-03-10 Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos BR0010380A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12382099P 1999-03-11 1999-03-11
PCT/US2000/006452 WO2000053168A2 (en) 1999-03-11 2000-03-10 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders

Publications (1)

Publication Number Publication Date
BR0010380A true BR0010380A (pt) 2002-03-26

Family

ID=22411088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010380-2A BR0010380A (pt) 1999-03-11 2000-03-10 Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos

Country Status (10)

Country Link
US (2) US6346517B1 (pt)
EP (1) EP1189663A2 (pt)
JP (1) JP2003526617A (pt)
CN (1) CN1378472A (pt)
AR (1) AR022909A1 (pt)
AU (1) AU3625500A (pt)
BR (1) BR0010380A (pt)
CA (1) CA2364252A1 (pt)
EA (1) EA200100965A1 (pt)
WO (1) WO2000053168A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US7192726B1 (en) * 1999-08-13 2007-03-20 Hemodyne, Inc. Method of using platelet contractile force and whole blood clot elastic modulus as clinical markers
US20050032745A1 (en) * 2000-05-04 2005-02-10 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US7651695B2 (en) * 2001-05-18 2010-01-26 Advanced Cardiovascular Systems, Inc. Medicated stents for the treatment of vascular disease
AU2002365408B2 (en) * 2001-11-26 2008-04-24 Genentech, Inc. Catheter composition and uses thereof
US7084118B2 (en) 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US20030199457A1 (en) * 2002-04-17 2003-10-23 El-Naggar Mawaheb M. Prevention and treatment of thromboembolic disorders associated with arterial & venous thrombosis
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2005027896A1 (ja) * 2003-09-19 2005-03-31 Kissei Pharmaceutical Co., Ltd. 併用医薬
GB2407040B (en) * 2003-10-15 2007-09-19 Sheikh Arshad Saeed Anti-platelet aggregation compositions
CN1322863C (zh) * 2004-10-29 2007-06-27 武汉远大制药集团股份有限公司 一种抑制血小板凝聚的注射液及其制备方法
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
WO2008070353A2 (en) 2006-11-07 2008-06-12 Genentech, Inc. Tissue plasminogen activator variant uses
GB2444956A (en) * 2006-12-19 2008-06-25 Pentapharm Ag An apparatus and method for measuring the coagulation characteristics of a test liquid
US9139876B1 (en) * 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US20110217301A1 (en) * 2009-12-22 2011-09-08 The Children's Research Instute Methods for treating or screening for compounds for the treatment of sepsis
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN104062375B (zh) * 2014-07-01 2015-08-26 合肥合源药业有限公司 一种同时检测药品及其对映异构体杂质的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582174B1 (fr) * 1985-05-15 1990-03-09 Thomson Csf Dispositif de chiffrement par substitutions-permutations
US5001754A (en) * 1990-02-01 1991-03-19 The Trustees Of Princeton University Encryption system and method
EP0730590B1 (en) 1993-11-24 2001-01-17 Dupont Pharmaceuticals Company isoxazoline and isoxazole fibrinogen receptor antagonists
GB2288519A (en) * 1994-04-05 1995-10-18 Ibm Data encryption
EP0735050B1 (en) 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions for inhibiting thrombogenesis
WO1997035615A1 (en) 1996-03-27 1997-10-02 Merck & Co., Inc. Compositions and methods for inhibiting clot formation
AU740941B2 (en) * 1998-02-02 2001-11-15 Correvio Llc Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist

Also Published As

Publication number Publication date
CN1378472A (zh) 2002-11-06
US20020068719A1 (en) 2002-06-06
US6346517B1 (en) 2002-02-12
AU3625500A (en) 2000-09-28
WO2000053168A2 (en) 2000-09-14
AR022909A1 (es) 2002-09-04
JP2003526617A (ja) 2003-09-09
CA2364252A1 (en) 2000-09-14
EP1189663A2 (en) 2002-03-27
WO2000053168A3 (en) 2002-01-24
EA200100965A1 (ru) 2002-08-29

Similar Documents

Publication Publication Date Title
BR0010380A (pt) Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
BRPI0414313A (pt) inibidores de citocinas
ES2193391T3 (es) Antagonistas muscarinicos.
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
EP1181013A4 (en) METHOD AND COMPOSITION FOR TREATING CANCER
BR0315304A (pt) Formulações com depósito para liberação controlada
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
HK1095139A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
WO2002058694A3 (en) Method of treating hematologic tumors and cancers using beta lapachone
BR0206046A (pt) Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
BR0009847A (pt) Kit de partes, método de preparação de um kit de partes, formulação farmacêutica, método de tratamento de uma condição na qual inibição de trombina é requerida ou desejada, e, uso de um inibidor de trombina, ou de um derivado farmaceuticamente aceitável do mesmo
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0010381A (pt) Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
BR0111785A (pt) Composições e métodos para tratamento de candidìase
BR9913348A (pt) Tratamento dos distúrbios da ansiedade

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007.